IDPH coordinates an influenza surveillance program in Illinois and collaborates with the Centers for Disease Control and Prevention (CDC) on the national surveillance program. This surveillance system is dependent on data and clinical specimens submitted from sentinel sites. If you are a physician, health care facility, or laboratory that either cares for patients with ILI and/or conducts virologic testing on influenza specimens and you wish to participate, there are two options explained below; the ILINet provider reporting program and the virologic sentinel program for specimen testing.
The ILINet provider program is an online reporting system where designated providers can log in and submit weekly ILI surveillance data. The total number of ill patients seen at your practice, in addition to the number seen only for ILI by age group is tracked and entered each week. This information is reported each Tuesday by close of business in an online database. Data from ILINet are used to evaluate the current influenza season, monitor influenza activity levels, identify novel strains and outbreaks, assess public health vaccination efforts in the community, and assist in vaccine formulations for the following season. Throughout the season, each site participating in the program will receive an emailed copy of the IDPH weekly influenza surveillance report and a final summary report at the end of the season.
To sign up for the ILINet provider program, please contact the IDPH Influenza Surveillance program by phone at 217-782-2016 or by email at email@example.com.
If you are a medical provider located within the City of Chicago, please contact the Chicago Department of Public Health’s Influenza Coordinator, Enrique Ramirez at 312-746-5911 or Enrique.firstname.lastname@example.org to register.
The virologic sentinel surveillance program is another part of the overall influenza surveillance program in Illinois and is a laboratory surveillance system involving a number of selected submission sites. This program consists of testing clinical specimens from ILI patients provided by sentinel sites at designated IDPH laboratories. A CDC FDA-cleared Influenza RT-PCR assay is used as well as culturing and subtyping. Virologic surveillance is a vital part of the influenza surveillance system as it allows the CDC, IDPH, local health departments, and the sentinel sites to identify types of influenza circulating in Illinois, aid in the development of next season’s vaccine, identify rare/novel Influenza A (H3N2v; H7) and B strains that may not be identified by commercial molecular assays; and identify and submit specimens to CDC for antiviral susceptibility testing and identification of shifts in the virus's genetic makeup.
We ask sentinel sites who sign up for participation in this program to send at least ten specimens each week to their designated IDPH laboratory for viral testing at no cost to the sentinel site. Prior approval or notice is not needed for specimen submission if the site is a registered participating sentinel site. Sentinels who participate in clinical specimen testing are provided their specimen results, with an average turn-around time of three days; however, this fluctuates depending on the volume of specimens being tested in a given week. Each site will be provided influenza collection and shipping materials, at no cost to the site, that contain specimen collection kits, submission forms, cold packs, and packaging & pre-paid mailing materials.
If you are interested in participating in the Virologic Sentinel Surveillance program, please contact one of the following for additional program details or to register:
- IDPH Communicable Disease Control Section, Influenza Program at 217-782-2016 or email@example.com
- Chicago IDPH Laboratory at 312-793-4760
- Springfield IDPH Laboratory at 217-782-6562
- Carbondale IDPH Laboratory at 618-457-5131
After signing up, all participating sites will receive additional, detailed specimen collection and shipping instructions from the IDPH laboratories prior to the start of the influenza season.